The Real-world Effect of Long-acting Injectable Antipsychotics on Annual Medical Costs of Korean Schizophrenia Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Schizophrenia is a severe and chronic mental disorder that significantly impacts cognitive, social, and occupational functions, leading to substantial economic burdens. Long-acting injectable (LAI) antipsychotics have been introduced to improve treatment adherence and outcomes, yet their economic impact remains debated. We aim to analyze the impact of LAIs on the medical costs of Korean schizophrenia patients. Methods: A retrospective analysis of 164 schizophrenia patients treated with LAI antipsychotics, paliperidone palmitate, and aripiprazole monohydrate at Korea University Guro Hospital between January 2017 and July 2022 was performed. Comparisons of inpatient department (IPD) and outpatient department (OPD) healthcare expenditures one year before and after LAI initiation were conducted. Results: LAIs led to an increase in annual OPD costs (1,437.44 ± 1,127.60 to 4,015.42 ± 1,204.59; units: 1,000 KRW) but significantly reduced IPD admission associated costs (3,826.06 ± 5,500.63 to 698.06 ± 3,619.38; units: 1,000 KRW). After LAI administration, there was an overall reduction in total annual healthcare costs (5,263.49 ± 5,333.11 to 4,713.48 ± 3,625.89; units: 1,000 KRW), but it was not statistically significant. Conclusion: Although the use of LAIs did not significantly lower the first-year medical costs of schizophrenia patients, they offer beneficial economic impacts over time by reducing hospitalization-associated costs. Future research should focus on long-term cost analyses and the impacts of newer LAI formulations.
Abstract
Objective: Schizophrenia is a severe and chronic mental disorder that significantly impacts cognitive, social, and occupational functions, leading to substantial economic burdens. Long-acting injectable (LAI) antipsychotics have been introduced to improve treatment adherence and outcomes, yet their economic impact remains debated. We aim to analyze the impact of LAIs on the medical costs of Korean schizophrenia patients. Methods: A retrospective analysis of 164 schizophrenia patients treated with LAI antipsychotics, paliperidone palmitate, and aripiprazole monohydrate at Korea University Guro Hospital between January 2017 and July 2022 was performed. Comparisons of inpatient department (IPD) and outpatient department (OPD) healthcare expenditures one year before and after LAI initiation were conducted. Results: LAIs led to an increase in annual OPD costs (1,437.44 ± 1,127.60 to 4,015.42 ± 1,204.59; units: 1,000 KRW) but significantly reduced IPD admission associated costs (3,826.06 ± 5,500.63 to 698.06 ± 3,619.38; units: 1,000 KRW). After LAI administration, there was an overall reduction in total annual healthcare costs (5,263.49 ± 5,333.11 to 4,713.48 ± 3,625.89; units: 1,000 KRW), but it was not statistically significant. Conclusion: Although the use of LAIs did not significantly lower the first-year medical costs of schizophrenia patients, they offer beneficial economic impacts over time by reducing hospitalization-associated costs. Future research should focus on long-term cost analyses and the impacts of newer LAI formulations.
참고문헌 (24)
- Chong HY, "Global economic burden of schizophrenia : a systematic review", Neuropsychiatr Dis Treat, 12, pp.357~373 (2016)
- Salgueiro M, "Long-acting injectable second-generation antipsychotics in first-episode psychosis : a narrative review", Int Clin Psychopharmacol, 34, pp.51~56 (2019)
- Keramatian K, "Long-acting injectable second-generation", atypical antipsychotics for the management of bipolar disorder : a systematic review, 2019, pp.33, 431~456
- Wei Y, "Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia", JAMA Netw Open, 5, pp.e2224163~ (2022)
- Marcus SC, "Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge", J Manag Care Spec Pharm, 21, pp.754~768 (2015)
- Wang GH, "Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia", J Manag Care Spec Pharm, 29, pp.884~895 (2023)
- Kwon S, "Thirty years of national health insurance in South Korea : lessons for achieving universal health care coverage", Health Policy Plan, 24, pp.63~71 (2009)
- "Paliperidone 6 mg" (2020)[URL]
- "Paliperidone palmitate 78 mg" (2012)[URL]
- "Aripiprazole monohydrate 300 mg" (2016)[URL]
- "Aripiprazole 10 mg" (2002)[URL]
- MacEwan JP, "Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics", Psychiatr Serv, 67, pp.1183~1188 (2016)
- Kim HO, "Real-world effectiveness of longacting injections for reducing recurrent hospitalizations in patients with schizophrenia", Ann Gen Psychiatry, 19, pp.1~ (2020)
- Lin D, "Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States : a systematic review and meta-analysis", CNS Drugs, 35, pp.469~481 (2021)
- Di Lorenzo R, "Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia : retrospective study in a real-world clinical setting", Neuropsychiatr Dis Treat, 15, pp.183~198 (2019)
- Mason K, "Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate", Ther Adv Psychopharmacol, 11, pp.20451253211029490~ (2021)
- Pilon D, "Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries", Curr Med Res Opin, 37, pp.1811~1819 (2021)
- Hwang TY, "Analysis of involuntary admissions in Korea through the admission management information system", Int J Law Psychiatry, 68, pp.101542~ (2020)
- Lin C, "The societal cost of schizophrenia : an updated systematic review of cost-of-illness studies", Pharmacoeconomics, 41, pp.139~153 (2023)
- Lin J, "Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia", J Behav Health Serv Res, 40, pp.355~366 (2013)
- Jukic V, "Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia", Value Health Reg Issues, 2, pp.181~188 (2013)
- Druais S, "Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France", Pharmacoeconomics, 34, pp.363~391 (2016)
- Zeidler J, "Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany", Appl Health Econ Health Policy, 11, pp.509~521 (2013)
- Einarson TR, "Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden", Nord J Psychiatry, 68, pp.416~427 (2014)